ArticleCancer gene therapy2005
Immunological properties and vaccine efficacy of murine dendritic cells simultaneously expressing melanoma-associated antigen and interleukin-12.
Article in Cancer gene therapy, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 51 citations in OpenAlex.
- Interleukin-12 Delivery Strategies and Advances in Tumor Immunotherapy.Current issues in molecular biology · 2024Review
- Article
- Mesothelin-specific cell-based vaccine generates antigen-specific immunity and potent antitumor effects by combining with IL-12 immunomodulator.Gene therapy · 2016Article
- New insights into IL-12-mediated tumor suppression.Cell death and differentiation · 2015Review
- Developments in Viral Vector-Based Vaccines.Vaccines · 2014Review
- Dendritic cells in cancer immunotherapy: vaccines and combination immunotherapies.Expert review of vaccines · 2013Review
- Enhanced activation of human dendritic cells by silencing SOCS1 and activating TLRs simultaneously.Cancer immunology, immunotherapy : CII · 2012Article
- Cellular immunotherapy using dendritic cells against multiple myeloma.The Korean journal of hematology · 2012Article
- Optimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and GM-CSF.Molecular therapy : the journal of the American Society of Gene Therapy · 2011Article
- Dendritic cells in cancer immunotherapy: vaccines or autologous transplants?Immunologic research · 2011Article
- Engineering dendritic cells to enhance cancer immunotherapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2011Review
- Enhanced transduction and replication of RGD-fiber modified adenovirus in primary T cells.PloS one · 2011Article
- Enhancement of dendritic cells as vaccines for cancer.Immunotherapy · 2010Review
- Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors.Seminars in immunology · 2010Review
- Gene carriers and transfection systems used in the recombination of dendritic cells for effective cancer immunotherapy.Clinical & developmental immunology · 2010Review
- Dendritic cells in immunotherapy of established cancer: Roles of signals 1, 2, 3 and 4.Current opinion in investigational drugs (London, England : 2000) · 2009Review
- Enhancement of dendritic cell-tumor fusion vaccine potency by indoleamine-pyrrole 2,3-dioxygenase inhibitor, 1-MT.Journal of cancer research and clinical oncology · 2008Article
- Immunotherapy of cancer by IL-12-based cytokine combinations.Expert opinion on biological therapy · 2007Review
- Recent developments in the use of adenoviruses and immunotoxins in cancer gene therapy.Cancer gene therapy · 2007Review
- Helper roles of NK and CD8+ T cells in the induction of tumor immunity. Polarized dendritic cells as cancer vaccines.Immunologic research · 2006Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin (IL)-12 is a key factor for inducing cellular immune responses, which play a central role in the eradication of cancer. In the present study, in order to create a dendritic cell (DC)-based vaccine capable of positively skewing immune response toward a cellular immunity-dominant state, we analyzed immunological characteristics and vaccine efficacy of DCs cotransduced with melanoma-associated antigen (gp100) and IL-12 gene (gp100+IL12/DCs) by using RGD fiber-mutant adenovirus vector (AdRGD), which enables highly efficient gene transduction into DCs. gp100+IL12/DCs could simultaneously express cytoplasmic gp100 and secretory IL-12 at levels comparable to DCs transduced with each gene alone. In comparison with DCs transduced with gp100 alone (gp100/DCs), upregulation of major histocompatibility complex class I, CD40, and CD86 molecules on the cell surface and more potent T-cell-stimulating ability for proliferation and interferon-gamma secretion were observed as characteristic changes in gp100+IL12/DCs. In addition, administration of gp100+IL12/DCs, which were prepared by a relatively low dose of AdRGD-IL12, could induce more potent tumor-specific cellular immunity in the murine B16BL6 melanoma model than vaccination with gp100/DCs. However, antitumor effect and B16BL6-specific cytotoxic T-lymphocyte activity in mice vaccinated with gp100+IL12/DCs diminished with increasing AdRGD-IL12 dose during gene transduction, and paralleled the decrease in presentation levels via MHC class I molecules for antigen transduced with another AdRGD. Collectively, our results suggested that optimization of combined vector dose was required for development of a more efficacious DC-based vaccine for cancer immunotherapy, which relied on genetic engineering to simultaneously express tumor-associated antigen and IL-12.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.